FDA accepts BLA for Genentech’s ranibizumab Port Delivery System

Jun 23, 2021

Genentech announced that the FDA has accepted the BLA for its Port Delivery System (PDS) with ranibizumab under Priority Review. Genentech is seeking approval for its PDS for the treatment of wet, or neovascular, age-related macular degeneration (AMD).

Print Page Mail Article